Literature DB >> 19581922

Obese men have higher-grade and larger tumors: an analysis of the duke prostate center database.

S J Freedland1, L L Bañez, L L Sun, N J Fitzsimons, J W Moul.   

Abstract

Obesity is associated with increased risk of positive surgical margins and prostate specific antigen (PSA) recurrence among men undergoing radical prostatectomy. To what degree positive margins contribute to poorer outcome is unclear. Thus, we sought to examine the association between body mass index (BMI) and more objective measures of tumor aggressiveness, tumor grade and size. We carried out a retrospective analysis of 2302 patients treated with radical prostatectomy at the Duke Prostate Center from 1988-2007. Tumor volume was calculated by multiplying prostate weight by percent of specimen involved with cancer. Associations between BMI and tumor volume and high-grade disease (Gleason >or=4+3) independent of pre-operative clinical characteristics of age, race, PSA, clinical stage, biopsy Gleason sum, and year of surgery were assessed using linear and logistic regression, respectively. Mean and median BMI among all subjects was 28.1 and 27.6 kg m(-2), respectively. Increased BMI was significantly associated with younger age (P<0.001), black race (P<0.001), more recent year of surgery (P<0.001), and positive surgical margins (P<0.001). After adjusting for multiple clinical pre-operative characteristics, higher BMI was associated with a greater percent of the prostate involved with cancer (P=0.003), increased tumor volume (P<0.001), and high-grade disease (P=0.007). Men with a BMI >or=35 kg m(2) had nearly 40% larger mean tumor volumes than normal weight men (5.1 versus 3.7 cc), after adjustment for multiple clinical characteristics. In this study, obese men undergoing radical prostatectomy had higher-grade and larger tumors, providing further evidence that obese men undergoing radical prostatectomy have more aggressive prostate cancers.

Entities:  

Mesh:

Year:  2009        PMID: 19581922     DOI: 10.1038/pcan.2009.11

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  51 in total

1.  The metabolic syndrome and the risk of prostate cancer under competing risks of death from other causes.

Authors:  Birgitta Grundmark; Hans Garmo; Massimo Loda; Christer Busch; Lars Holmberg; Björn Zethelius
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07-20       Impact factor: 4.254

2.  Obesity has multifaceted impact on biochemical recurrence of prostate cancer: a dose-response meta-analysis of 36,927 patients.

Authors:  Meng-Bo Hu; Hua Xu; Pei-De Bai; Hao-Wen Jiang; Qiang Ding
Journal:  Med Oncol       Date:  2014-01-05       Impact factor: 3.064

Review 3.  Urological aspects of the metabolic syndrome.

Authors:  Jan Hammarsten; Ralph Peeker
Journal:  Nat Rev Urol       Date:  2011-08-02       Impact factor: 14.432

4.  Predictive value of digital rectal examination for prostate cancer detection is modified by obesity.

Authors:  D I Chu; C De Nunzio; L Gerber; J-A Thomas; E E Calloway; S Albisinni; C Senocak; M G McKeever; D M Moreira; A Tubaro; J W Moul; S J Freedland; L L Bañez
Journal:  Prostate Cancer Prostatic Dis       Date:  2011-07-05       Impact factor: 5.554

Review 5.  Diabetes and cancer (2): evaluating the impact of diabetes on mortality in patients with cancer.

Authors:  A G Renehan; H-C Yeh; J A Johnson; S H Wild; E A M Gale; H Møller
Journal:  Diabetologia       Date:  2012-04-04       Impact factor: 10.122

6.  Metabolic abnormalities linked to an increased cardiovascular risk are associated with high-grade prostate cancer: a single biopsy cohort analysis.

Authors:  C De Nunzio; G Truscelli; A Trucchi; S Petta; M Tubaro; M Gacci; C Gaudio; F Presicce; A Tubaro
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-10-06       Impact factor: 5.554

7.  Severe obesity is associated with symptomatic presentation, higher parathyroid hormone levels, and increased gland weight in primary hyperparathyroidism.

Authors:  Mohamed Abdelgadir Adam; Brian R Untch; Melissa E Danko; Sandra Stinnett; Darshana Dixit; James Koh; Jeffrey R Marks; John A Olson
Journal:  J Clin Endocrinol Metab       Date:  2010-08-04       Impact factor: 5.958

8.  Body mass index as a classifier to predict biochemical recurrence after radical prostatectomy in patients with lower prostate-specific antigen levels.

Authors:  Keisuke Goto; Hirotaka Nagamatsu; Jun Teishima; Yuki Kohada; Shinsuke Fujii; Yoshimasa Kurimura; Koji Mita; Masanobu Shigeta; Satoshi Maruyama; Yoji Inoue; Mitsuru Nakahara; Akio Matsubara
Journal:  Mol Clin Oncol       Date:  2017-04-10

Review 9.  [Metabolic syndrome and prostate cancer].

Authors:  B J Schmitz-Dräger; G Lümmen; E Bismarck; C Fischer
Journal:  Urologe A       Date:  2013-06       Impact factor: 0.639

10.  Association of body mass index and prostate cancer mortality.

Authors:  Reina Haque; Stephen K Van Den Eeden; Lauren P Wallner; Kathryn Richert-Boe; Bhaskar Kallakury; Renyi Wang; Sheila Weinmann
Journal:  Obes Res Clin Pract       Date:  2013-08-06       Impact factor: 2.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.